Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tafenoquine Succinate,Chloroquine Phosphate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Medicines for Malaria Venture
Deal Size : Not Applicable
Deal Type : Not Applicable
GSK and MMV Launch New Medicine to Prevent Plasmodium vivax Malaria Relapse
Details : Kozenis (tafenoquine) is the first single-dose, oral, hematin polymerization inhibitor co-administered with chloroquine for preventing P. vivax malaria relapse, launched in Thailand and Brazil.
Brand Name : Kozenis
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 06, 2024
Lead Product(s) : Tafenoquine Succinate,Chloroquine Phosphate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Medicines for Malaria Venture
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Chloroquine Phosphate,Azithromycin,Interferon Beta 1B
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Bayer AG
Deal Size : $1.1 million
Deal Type : Partnership
Details : Bayer and PHRI together will conduct two studies that will evaluate the safety and efficacy of different combination therapies including Bayer’s chloroquine and interferon beta-1b.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 21, 2020
Lead Product(s) : Chloroquine Phosphate,Azithromycin,Interferon Beta 1B
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Bayer AG
Deal Size : $1.1 million
Deal Type : Partnership
Lead Product(s) : Chloroquine Phosphate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : U.S. Government
Deal Size : Undisclosed
Deal Type : Partnership
Bayer Partners with U.S. Government on Major Product Donation to Fight Coronavirus
Details : Bayer is working with appropriate agencies on an Emergency Use Authorization for the drug’s use in the U.S.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 19, 2020
Lead Product(s) : Chloroquine Phosphate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : U.S. Government
Deal Size : Undisclosed
Deal Type : Partnership
LOOKING FOR A SUPPLIER?